These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19107333)

  • 1. Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside.
    Furukawa T
    J Gastroenterol; 2008; 43(12):905-11. PubMed ID: 19107333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
    Su CC
    Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief overview of selected approaches in targeting pancreatic adenocarcinoma.
    Samore WR; Gondi CS
    Expert Opin Investig Drugs; 2014 Jun; 23(6):793-807. PubMed ID: 24673265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs in the treatment of pancreatic cancer.
    Mahalingam D; Kelly KR; Swords RT; Carew J; Nawrocki ST; Giles FJ
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):311-28. PubMed ID: 19466902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting signal transduction in pancreatic cancer treatment.
    Yeh JJ; Der CJ
    Expert Opin Ther Targets; 2007 May; 11(5):673-94. PubMed ID: 17465725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
    Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel agents for advanced pancreatic cancer.
    Akinleye A; Iragavarapu C; Furqan M; Cang S; Liu D
    Oncotarget; 2015 Nov; 6(37):39521-37. PubMed ID: 26369833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging protein kinase inhibitors for treating pancreatic cancer.
    Furuse J; Nagashima F
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):77-86. PubMed ID: 28253828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside.
    Yang F; Jin C; Jiang Y; Li J; Di Y; Ni Q; Fu D
    Cancer Treat Rev; 2011 Dec; 37(8):633-42. PubMed ID: 21330062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in Ras therapeutics in pancreatic cancer.
    Choi M; Bien H; Mofunanya A; Powers S
    Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.
    He L; Wu Y; Lin L; Wang J; Wu Y; Chen Y; Yi Z; Liu M; Pang X
    Cancer Sci; 2011 Jan; 102(1):219-25. PubMed ID: 21087351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targeting therapy for pancreatic cancer.
    Xiong HQ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S69-77. PubMed ID: 15316751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic Cancer and Therapy: Role and Regulation of Cancer Stem Cells.
    Barman S; Fatima I; Singh AB; Dhawan P
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring Signaling Pathways and Pancreatic Cancer Treatment Approaches Using Genetic Models.
    Khader S; Thyagarajan A; Sahu RP
    Mini Rev Med Chem; 2019; 19(14):1112-1125. PubMed ID: 30924420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
    Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agents targeting the Hedgehog pathway for pancreatic cancer treatment.
    Bisht S; Brossart P; Maitra A; Feldmann G
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1387-98. PubMed ID: 21154121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cucurmosin induces apoptosis of BxPC-3 human pancreatic cancer cells via inactivation of the EGFR signaling pathway.
    Zhang B; Huang H; Xie J; Xu C; Chen M; Wang C; Yang A; Yin Q
    Oncol Rep; 2012 Mar; 27(3):891-7. PubMed ID: 22139427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
    Zanini S; Renzi S; Giovinazzo F; Bermano G
    Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
    Asati V; Mahapatra DK; Bharti SK
    Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.